Common pitfalls in drug target Mendelian randomization and how to avoid them

期刊论文
出版模式：

开放获取
发表日期：

2024年10月15日

查看全文

Dipender Gill,
Marie-Joe Dib,
Héléne T. Cronjé,
Ville Karhunen,
Benjamin Woolf,
Eloi Gagnon,
Iyas Daghlas,
Michael Nyberg,
Donald Drakeman,
Stephen Burgess

摘要

Background

Drug target Mendelian randomization describes the use of genetic variants as instrumental variables for studying the effects of pharmacological agents. The paradigm can be used to inform on all aspects of drug development and has become increasingly popular over the last decade, particularly given the time- and cost-efficiency with which it can be performed even before commencing clinical studies.

Main body

In this review, we describe the recent emergence of drug target Mendelian randomization, its common pitfalls, how best to address them, as well as potential future directions. Throughout, we offer advice based on our experiences on how to approach these types of studies, which we hope will be useful for both practitioners and those translating the findings from such work.

Conclusions

Drug target Mendelian randomization is nuanced and requires a combination of biological, statistical, genetic, epidemiological, clinical, and pharmaceutical expertise to be utilized to its full potential. Unfortunately, these skillsets are relatively infrequently combined in any given study.